[Sclerema and scleredema of the newborn].

D. Barbieri,J. de Araujo

1956-07-01

Abstract:

What problem does this paper attempt to address?

From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?

F. Zécri

DOI: https://doi.org/10.1016/j.cbpa.2016.04.014

IF: 8.972

2016-06-01

Current Opinion in Chemical Biology

Abstract:
Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Yan Wei,Zhili Zhang,Feng Wang,Shuihong Zhou

DOI: https://doi.org/10.3892/etm.2017.5501

IF: 2.7

2017-01-01

Experimental and Therapeutic Medicine

Abstract:To identify a novel and effective therapy for allergic rhinitis and asthma (ARA), the present study focused on treatment with tumor growth factor (TGF)-β1 neutralizing antibody. In the present study, four medications were administered to mice with ovalbumin-induced allergic inflammation. Allergic symptoms in the lungs and nasal mucosa were evaluated by detecting the secretion of cytokines from helper T cells (Th) in the peripheral blood, nasal lavage fluid and bronchoalveolar lavage fluid using ELISA. Defects in regulatory T (Treg) cells in peripheral blood mononuclear cells were also detected using flow cytometry. Furthermore, the expression of TGF-β1 and activation of Smad2/3 pathways were assessed using immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction, and western blotting. It was observed that TGF-β1 neutralizing antibody inhibited symptoms of inflammation in the upper and lower airways. TGF-β1 neutralizing antibody also restored the Th1/Th2 balance and ameliorated Treg cell defects induced by ARA. Furthermore, the therapeutic effects of TGF-β1 neutralizing antibody were related to its inhibitory effects on TGF-β1 expression and Smad2/3 signaling in nasal and lung tissues. Therefore, TGF-β1 neutralizing antibody may be an effective medicine for the treatment of ARA.
Inhibition of human lymphocyte reactivity by plasma fibronectin in vitro

J C Schultz,N T Shahidi

DOI: https://doi.org/10.1046/j.1537-2995.1990.30991048784.x

Transfusion

Abstract:The effect of purified human plasma fibronectin (FN) on the reactivity of human lymphocyte-rich mononuclear cells to mitogens and allogeneic cell interactions was studied. Concentrations of FN from 25 to 100 micrograms per 250 microL of culture consistently depressed phytohemagglutinin (PHA) responses. To exert an inhibitory effect, FN must be present within 20 hours after the addition of PHA to cells, and, therefore, it appears to interfere with early events in the transformation process. Increasing the concentration of PHA failed to reduce the inhibitory effect of FN, which suggests that the depressed response was not the result of FN-PHA complex formation, which would reduce the amount of mitogen available for stimulation. This possibility was supported by the finding that FN also inhibited the mixed lymphocyte response (MLR), in a reaction that was not dependent on the activity of soluble antigen or mitogen. In contrast, the stimulation of lymphocytes to undergo transformation that is induced by the nonlectin mitogen, sodium periodate, was unaffected by FN. Periodate-treated cells are, however, already stimulated to undergo transformation, prior to their exposure to FN. FN did not interfere with the activity of interleukin-2, nor did it indirectly regulate lymphocyte responses by modifying the production and/or effect of humoral regulatory factors released from the adherent accessory cells (macrophages). These studies show that FN is a potent immunosuppressive agent in vitro.
Low molecular weight heparin inhibits circulating fibrocytes differentiation by modulating neuronal nitric oxide synthase and TGF-β1/Smad pathway.

Xudong Xie,Liangfeng Zhu,Zhongying Fu,Xiaogang Guo,Kan Wang,Xiaosheng Hu,Junzhu Chen

DOI: https://doi.org/10.1159/000343334

2012-01-01

Cellular Physiology and Biochemistry

Abstract:Background/Aims: Circulating fibrocytes (CFs) have been placed at the center of a number of fibrosing conditions. Recently, attention has been drawn to the non-anticoagulant activities of low molecular weight heparin (LH), especially its anti-fibrotic effects. The purpose of this study was to investigate the effects of LH on CFs differentiation and possible underlying mechanisms. Methods/Results: CFs were cultured from human peripheral blood mononuclear cells and identified by dual-immunofluorescence staining. Incubation with LH inhibited CFs trans-differentiation by upregulating CD34 and downregulating pro-Collagen I and a-SMA in a concentration- and time-dependent manner, all of which were detected by flow cytometry. Similar effects were observed after incubation with L-NAME, an inhibitor of NOS. NO production was measured by Griess methods and markedly decreased in CFs treated with LH. Three NOS isoforms were assessed by western blot and nNOS was the predominant isoform involved in this process. Additionally, LH and L-NAME had similar down-regulating effects on the expression of TGF-beta 1 and pSmad2/3, which indicated that TGF-beta/Smad pathway might be a downstream signaling of nNOS/NO during LH treatment. Conclusion: These results suggested that LH could exhibit anti-fibrotic effects by inhibiting CFs transdifferentiation, in which the involvement of nNOS/NO and TGF-beta/Smad pathway were identified. Copyright (c) 2012 S. Karger AG, Basel
Prospective Evaluation of Subjects With Chronic Asymptomatic Pancreatic Hyperenzymemia

A. Amodio,R. Manfredi,A. Katsotourchi,A. Gabbrielli,L. Benini,R. Mucelli,I. Vantini,L. Frulloni

DOI: https://doi.org/10.1038/ajg.2012.125

2012-07-01

Abstract:
Protective Effect of an Antibody Against Specific Extracellular Domain of TLR2 on Agonists-Driven Inflammatory and Allergic Response.

Tianwu Guo,Jun Cai,Yanxia Peng,Lifang Zhang,Qiaofen Lan,Yanwen Chen,Huanjin Liao,Tong Xie,Ping Wu,Qingjun Pan

DOI: https://doi.org/10.1155/2016/9803846

2016-01-01

BioMed Research International

Abstract:Specific blocking strategies of TLR2-mediated inflammatory signaling and hypersensitivity reactions may offer novel therapeutic strategies to prevent a variety of diseases. In this study, we investigated the blocking effects of a new anti-TLR2 antibody anti-T20 against a 20 mer peptide T20 located in the extracellular specific domain of mouse TLR2. In addition, the effects of the anti-T20 in vitro, measuring the inhibition of the IL-6 and TNF-α production in response to PGN, LTA, and Pam3CSK4-stimulated RAW264.7 cells, were determined. In vivo, the effects of anti-T20 on a lethal anaphylaxis model using PGN-challenged OVA allergic mice, including the rectal temperature and mortality, and serum levels of TNF-α, IL-6, and LTC4 were assayed. The results showed that anti-T20 specifically bound to TLR2 and significantly inhibited PGN, LTA, and Pam3CSK4-driven TNF-α and IL-6 production by RAW264.7 cells. Also, anti-T20 protected OVA allergic mice from PGN-induced lethal anaphylaxis, and the serum levels of TNF-α, IL-6, and LTC4 of anti-T20 treated PGN-challenged OVA allergic mice were decreased as compared to isotype control of anti-T20 treated mice. In summary, this study produced a new antibody against the specific extracellular domain of TLR2 which has protective effect on TLR2 agonists-driven inflammatory and allergic response.
A Novel Anti-Tissue Factor Monoclonal Antibody with Anticoagulant Potency Derived from Synthesized Multiple Antigenic Peptide Through Blocking FX Combination with TF

Zhuo-Chun Peng,Xu Cai,Yu-Gao Zhang,De-Sheng Kong,Hong-Shen Guo,Wang Liang,Qi-Qun Tang,Hou-Yan Song,Duan Ma

DOI: https://doi.org/10.1016/j.thromres.2007.03.001

IF: 10.407

2007-01-01

Thrombosis Research

Abstract:Tissue factor (TF) has been implicated in the pathogenesis of various thrombotic disorders. Monoclonal antibodies (mAb) that specifically target TF may have potential as antithrombotic therapy. We designed a unique TF peptide (TFP) that was specific for the binding site to factor X (FX). This peptide was used to develop TF mAb that block the coagulation cascade by interfering with the combination of FX with the TF/FVIIa complex. Chemically synthesized TFP coupled to polylysine matrix was used as multiple antigenic peptide (TF-MAP) and this was used to immunize Balb/c mice for the preparation of hybridomas. One hybridoma cell line released an antibody, named TF4A12, which had high anticoagulant potency (by dilute prothrombin time assay). Western blotting showed that TF4A12 could bind TF-MAP and the soluble TF extracellular domain (sTF(1-219)). Results of FX activation assay and amidolytic activity assay showed that the anticoagulant ability of TF4A12 is due to blocking FX, but not FVII, binding to TF. Our study identified an efficient method of developing TF mAb that could block the coagulation cascade.
Inflammatory Cytokine-Neutralizing Antibody Treatment Prevented Increases in Follicular Helper T Cells and Follicular Regulatory T Cells in a Mouse Model of Arthritis.

Xingyue Zeng,Songsong Lu,Meng Li,Mohan Zheng,Tianci Liu,Rui Kang,Lijuan Xu,Qinzhu Xu,Ying Song,Chen Liu

DOI: https://doi.org/10.2147/jir.s355720

IF: 4.5

2022-01-01

Journal of Inflammation Research

Abstract:Background:Follicular T helper (TFH) and follicular regulatory T (TFR) cells play important roles in humoral immunity. Nevertheless, their significance in rheumatoid arthritis (RA) pathogenesis has not been fully elucidated. As an important treatment strategy, the effect of inflammatory factor-neutralizing antibodies on TFH and TFR in RA remains unclear.Methods:We used the collagen-induced arthritis (CIA) mouse model to illustrate the quantity and functional changes in TFH and TFR cells. The changes of plasmablast, TFH and TFR cells in the spleen and peripheral blood of CIA mice were analyzed by flow cytometry. The levels of TFH and TFR and their functional subsets in the spleen after anti-inflammatory antibody treatment were analyzed and compared. The functional changes of TFH and TFR in CIA mice before and after treatment were detected by in vitro culture experiments.Results:Plasmablast levels were increased in CIA spleen and peripheral blood and both TFH and TFR cell levels were upregulated. TFH and TFR cells were decreased significantly after the anti-inflammatory antibody treatment. TIGIT+ and TIGIT+CD226- TFH cells in CIA mouse spleen were elevated and PD-1 and ICOS expression on spleen TFH and TFR cells was increased. Both the ability of TFH cells to secrete IL-21 and aid B cells and the ability of TFR cells to secrete IL-10 and inhibit TFH cells were enhanced in the CIA mice. After antibody treatment, the cell subsets and functions were recovered.Conclusion:Germinal center TFH and TFR cells were increased and their functions were enhanced. With inflammatory factor-neutralizing antibody treatment, TFH and TFR subsets and their functions returned to normal. These findings provide important information on the dynamics of humoral immune-related cell subsets in RA and the effects of treatment on them.
Locally instilled tumor necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs.

Yi Luo,Zhonghua Pang,Qian Zhu,Xing Cai,Yuan Yin,Min Wang,Jie Zhu,Jiangning Chen,Ke Zeng,Chenyu Zhang,Junfeng Zhang

DOI: https://doi.org/10.1002/jgm.2631

2012-01-01

Abstract:Background Anti-tumor necrosis factor (TNF)-a therapeutics has the potential to alleviate allergic inflammation. However, in previous studies, the systemic administration of anti-TNF-a agents was frequently accompanied by many adverse effects, such as infection, immunogenicity and malignancy. Efforts are made in the present study to evaluate whether or not local administration of TNF-a antisense oligonucleotide would inhibit allergic airway inflammation and influence systemic immune responses in an ovalbumin-induced asthmatic murine model. Methods The treatment effects of TNF-a antisense oligonucleotide on mice, as well as the alternative proportion of regulatory T cells and TH2 cells, were examined and compared with untreated mice. Results Local administration of TNF-a antisense oligonucleotide resulted in significantly inhibited TNF-a expression, remarkably decreased inflammatory cell infiltration and dramatically reduced mucus hypersecretion. These treatment effects were associated with induced CD4+CD25+Foxp3+ regulatory T cells, reduced TH2 cells and generally decreased TH2-type cytokines expression in bronchoalveolar lavage fluid. Systemic immunosuppression was not triggered by local antisense oligonucleotide administration because the proportion of CD4+CD25+Foxp3+ regulatory T cells in the blood, thymus or spleen was not affected. Attenuated 4-1BBL expression was likely involved in the alternative proportion of T cells. Conclusions These findings demonstrate that local administration of TNF-a antisense oligonucleotide contributes to anti-inflammatory action via the enhancement of regulatory T cells-mediated immune tolerance, which is not accompanied by systemic immunosuppression associated with systemically-induced regulatory T cells. Copyright (c) 2012 John Wiley & Sons, Ltd.
Formononetin Inhibits Mast Cell Degranulation to Ameliorate Compound 48/80-Induced Pseudoallergic Reactions

Zi-Wen Zhou,Xue-Yan Zhu,Shu-Ying Li,Si-En Lin,Yu-Han Zhu,Kunmei Ji,Jia-Jie Chen

DOI: https://doi.org/10.3390/molecules28135271

IF: 4.6

2023-07-07

Molecules

Abstract:Formononetin (FNT) is a plant-derived isoflavone natural product with anti-inflammatory, antioxidant, and anti-allergic properties. We showed previously that FNT inhibits immunoglobulin E (IgE)-dependent mast cell (MC) activation, but the effect of FNT on IgE-independent MC activation is yet unknown. Our aim was to investigate the effects and possible mechanisms of action of FNT on IgE-independent MC activation and pseudoallergic inflammation. We studied the effects of FNT on MC degranulation in vitro with a cell culture model using compound C48/80 to stimulate either mouse bone marrow-derived mast cells (BMMCs) or RBL-2H3 cells. We subsequently measured β-hexosaminase and histamine release, the expression of inflammatory factors, cell morphological changes, and changes in NF-κB signaling. We also studied the effects of FNT in several in vivo murine models of allergic reaction: C48/80-mediated passive cutaneous anaphylaxis (PCA), active systemic anaphylaxis (ASA), and 2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). The results showed that FNT inhibited IgE-independent degranulation of MCs, evaluated by a decrease in the release of β-hexosaminase and histamine and a decreased expression of inflammatory factors. Additionally, FNT reduced cytomorphological elongation and F-actin reorganization and attenuated NF-κB p65 phosphorylation and NF-κB-dependent promoter activity. Moreover, the administration of FNT alleviated pseudoallergic responses in vivo in mouse models of C48/80-stimulated PCA and ASA, and DNCB-induced AD. In conclusion, we suggest that FNT may be a novel anti-allergic drug with great potential to alleviate pseudoallergic responses via the inhibition of IgE-independent MC degranulation and NF-κB signaling.

chemistry, multidisciplinary,biochemistry & molecular biology
[Delayed growth with raised circulating growth hormone and incapacity to produce somatomedin (dwarfism of Laron type)].

R. Rappaport,P. Czernichow,C. Prévost,M. Jullien

Abstract:
TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism

Felicia M Bloemendaal,Pim J Koelink,Karin A van Schie,Theo Rispens,Charlotte P Peters,Christianne J Buskens,Jarmila D van der Bilt,Willem A Bemelman,Hannelie Korf,João G Sabino,Cyriel Y Ponsioen,Anje A Te Velde,Geert R A M D'Haens,Severine Vermeire,Gijs R van den Brink,Manon E Wildenberg,Anje A te Velde,Geert R A M D’Haens

DOI: https://doi.org/10.1093/ecco-jcc/jjy075

2018-05-30

Journal of Crohn's and Colitis

Abstract:BACKGROUND AND AIMS: We have recently shown that the mode of action of IgG1 anti-tumour necrosis factor [TNF] antibodies in inflammatory bowel disease [IBD] requires Fcγ-receptor [FcγR] engagement on macrophages. Here we examine the effect of Fcγ-receptor signalling by anti-TNF on macrophage IL-12/IL-23 secretion.METHODS: Cytokine production by human inflammatory macrophages was assessed at the level of RNA and protein. TNF-anti-TNF immune complex formation was determined by size-exclusion chromatography and signalling visualized by immunofluorescence. IL-12/IL-23p40 was measured in CD14+ lamina propria cells from IBD patients.RESULTS: Infliximab and adalimumab potently suppressed IL-12/IL-23 production by inflammatory macrophages, but Fab' fragment certolizumab did not. IL-12/IL-23 suppression depended on Syk activity and was mediated at the level of IL-12/IL-23p40 mRNA. Etanercept, a soluble TNF receptor fused to an Fc-region, did not inhibit IL-12/L-23 secretion, suggesting that the presence of an Fc-region was not sufficient. Infliximab and adalimumab formed immune complexes with soluble TNF whereas etanercept did not, suggesting that FcγR-mediated suppression of IL-12/IL-23 required the formation of immune complexes. Indeed, non-specific IgG1 immune complexes, but not uncomplexed IgG1, similarly suppressed IL-12/IL-23 secretion. Finally, infliximab significantly decreased IL-12/IL-23p40 production in myeloid cells isolated from the lamina propria of IBD patients.CONCLUSIONS: TNF-anti-TNF antibody immune complexes potently inhibit IL-12/IL-23 expression by inflammatory macrophages. Our data suggest that anti-TNFs and antibodies against IL-12/IL-23 may therefore have partially overlapping modes of action in patients with IBD.
Life-threatening right ventricular thrombosis in association with phospholipid antibodies.

S. O'hickey,C. Skinner,J. Beattie

DOI: https://doi.org/10.1136/hrt.70.3.279

1993-09-01

Abstract:An 18 year old man presented with cough and dyspnoea caused by pulmonary infarction. A large friable mass of organising thrombus in an anatomically normal right ventricle was identified as an embolic source. The acute illness was associated with raised titres of anticardiolipin antibodies, one of the antiphospholipid group. This thrombus recurred after surgical removal but subsequently was dissipated after treatment with oral corticosteroids and long-term oral anticoagulation.
Diagnosis and Management of Dry-Eye Syndrome

K. F. Tabbara,M. Wagoner

DOI: https://doi.org/10.1097/00004397-199603620-00008

International Ophthalmology Clinics

Abstract:
Anticoagulation Inhibition Effects of the Monoclonal Antibody Aginst the Recombinant Human Tissue Factor Pathway Inhibitor 1 on Rhtfpi

CAI Xü,BAI Hao,KONG De-sheng,GUO Hong-shen,LIANG Wang,SONG Hou-yan,MA Duan

DOI: https://doi.org/10.3969/j.issn.1001-6325.2006.11.005

2006-01-01

Abstract:Objective To develop the monoclonal antibody for the anti-recombinant human tissue factor pathway inhibitor 1(rhTFPI-1) and to investigate its anticoagulation inhibition effects on rhTFPI.Methods We injected the hybridoma cells that secrete anti-rhTFPI-1 McAb to the Balb/C mouse pretreated with pristane to induce ascites.The ascites were purified with rprotein A affinity chromatograghy.The purified anti-rhTFPI-1 McAb was analyzed by SDS-PAGE and Western blot.The inhibition effects of anti-rhTFPI1 McAb on rhTFPI-1 were measured by chromophoric substrate assay.Results The purity of the anti-rhTFPI-1 McAb was 98% by SDS-PAGE analysis.Western blot demonstrated that the anti-rhTFPI-1 McAb specifically reacted with(rhTFPI-1.) The chromophoric substrate assay showed that the anti-rhTFPI-1 McAb could effectively block the(anti-TF/FVIIa) activity,but not the anti-FXa activity,of rhTFPI-1.The residual TF/FVIIa activity was up to(86% at (8 mg/L)) anti-rhTFPI-1 McAb,but the residual FXa activity was 48.4% at (80 mg/L) anti-rhTFPI-1 McAb.(Conclusion) The anti-rhTFPI-1 McAb effectivelyinhibits the activities of rhTFPI-1.
Locally instilled tumor necrosis factor α antisense oligonucleotide contributes to inhibition of TH2-driven pulmonary fibrosis via induced CD4+CD25+Foxp3+ regulatory T cells

Yi Luo,Min Wang,Zhonghua Pang,Fengtao Jiang,Jiangning Chen,Junfeng Zhang

DOI: https://doi.org/10.1002/jgm.2750

2013-01-01

Abstract:BackgroundAnti-tumor necrosis factor therapeutics has the potential to alleviate pulmonary fibrosis. However, the systemic administration of anti-tumor necrosis factor agents has brought about contradictory results and frequent adverse effects, such as infections, immunogenicity and malignancies, amongst others. In the present study, we attempted the local administration of tumor necrosis factor antisense oligonucleotide and evaluated the treatment effects on pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis mouse model. MethodsFlow cytometry for regulatory T cells, reverse transcriptase-polymerase chain reaction for crucial gene expression, western blotting for crucial protein products, immunofluorescent analysis for T(H)2 cells and myofibroblasts, as well as histology analysis for pathological examination, were used. ResultsBy local administration of tumor necrosis factor antisense oligonucleotide, we investigated whether tumor necrosis factor expression in epithelial cells was significantly inhibited and extracellular matrix overexpression was dramatically reduced. These treatment effects were associated with induced regulatory T cells, reduced T(H)2 cells and generally decreased T(H)2-type cytokine expression. Systemic immunosuppression was not triggered by local antisense oligonucleotide administration because the proportion of regulatory T cells in the blood, thymus or spleen was not affected. ConclusionsThese findings demonstrate that local administration of tumor necrosis factor antisense oligonucleotide contributes to anti-fibrotic action via a sustained up-regulated level of regulatory T cells, which inhibits T(H)2-biased responses, pro-fibrotic mediator production and extracellular matrix deposition, with no systemic immunosupression associated with systemically induced regulatory T cells. Copyright (c) 2013 John Wiley & Sons, Ltd.
Monovalent Fc Receptor Blockade by an Anti–fcγ Receptor/albumin Fusion Protein Ameliorates Murine ITP with Abrogated Toxicity

Xiaojie Yu,Melissa Menard,Jozsef Prechl,Varsha Bhakta,William P. Sheffield,Alan H. Lazarus

DOI: https://doi.org/10.1182/blood-2015-08-664656

IF: 20.3

2016-01-01

Blood

Abstract:Patients with immune thrombocytopenia (ITP) commonly have antiplatelet antibodies that cause thrombocytopenia through Fcγ receptors (FcγRs). Antibodies specific for FcγRs, designed to inhibit antibody-FcγR interaction, had been shown to improve ITP in refractory human patients. However, the development of such FcγR-specific antibodies has stalled because of adverse events, a phenomenon recapitulated in mouse models. One hypothesis behind these adverse events involved the function of the Fc region of the antibody, which engages FcγRs, leading to inflammatory responses. Unfortunately, inhibition of Fc function by deglycosylation failed to prevent this inflammatory response. In this work, we hypothesize that the bivalent antigen-binding fragment regions of immunoglobulin G are sufficient to trigger adverse events and have reasoned that designing a monovalent targeting strategy could circumvent the inflammatory response. To this end, we generated a fusion protein comprising a monovalent human FcγRIIIA-specific antibody linked in tandem to human serum albumin, which retained FcγR-binding activity in vitro. To evaluate clinically relevant in vivo FcγR-blocking function and inflammatory effects, we generated a murine version targeting the murine FcγRIII linked to murine albumin in a passive murine ITP model. Monovalent blocking of FcγR function dramatically inhibited antibody-dependent murine ITP and successfully circumvented the inflammatory response as assessed by changes in body temperature, basophil activation, and basophil depletion. Consistent with our hypothesis, in vivo cross-linking of the fusion protein induced these inflammatory effects, recapitulating the adverse events of the parent antibody. Thus, monovalent blocking of FcγR function demonstrates a proof of concept to successfully treat FcγR-mediated autoimmune diseases.
Expression of vascular cell adhesion molecule-1 by vascular endothelial cells in immune and nonimmune inflammatory reactions in the skin.

A A Harrison,C J Stocker,P T Chapman,Y T Tsang,T Y Huehns,R H Gundel,A M Peters,K A Davies,A J George,M K Robinson,D O Haskard

DOI: https://doi.org/10.4049/jimmunol.159.9.4546

1997-11-01

The Journal of Immunology

Abstract:Abstract Expression of VCAM-1 was compared with that of E-selectin in cytokine-induced lesions and in delayed-type hypersensitivity reactions to tuberculin purified protein derivative (PPD) in pig skin. Lumenally expressed Ags were quantified by measuring localization in skin of i.v. injected (111)In-mAb 10.2C7 (anti-vascular cell adhesion molecule-1 (anti-VCAM-1), (125)I-mAb 1.2B6 (anti-E-selectin), and (99m)Tc-MOPC21 (control IgG1). Anti-VCAM-1 mAb uptake was greater following intradermal (i.d.) injection of TNF-alpha than following injection of IL-1, while the two cytokines induced similar uptake of anti-E-selectin. In immunologically naive pigs there was no detectable increase in anti-VCAM-1 after i.d. injection of PPD, although anti-E-selectin uptake was increased at 3 and 6 h. In contrast, i.d. injection of PPD in sensitized pigs led to increased uptake of both anti-VCAM-1 and anti-E-selectin at 6, 8, 24, and 48 h, each of which was significantly greater than the uptake of control IgG1 into the same lesions (each p < 0.01). Anti-TNF-alpha mAb abolished the increased uptake of anti-VCAM-1 3 and 8 h following i.d. injection of PPD in sensitized pigs and significantly inhibited uptake at 24 h (p = 0.0025), but did not significantly reduce uptake of anti-E-selectin. We conclude that in this delayed-type hypersensitivity model 1) E-selectin expression by endothelial cells follows sequential Ag nonspecific and immune-specific phases, 2) increased VCAM-1 expression by endothelial cells is only seen in sensitized animals, and 3) expression of VCAM-1 appears to be relatively more dependent on TNF-alpha than E-selectin. Differential expression of E-selectin and VCAM-1 may influence the leukocytic infiltrate during the course of nonspecific and immune-specific inflammatory reactions.

immunology
Extraordinarily Potent Proinflammatory Properties of Lactoferrin-Containing Immunocomplexes Against Human Monocytes and Macrophages

Lulu Hu,Xiaomin Hu,Kai Long,Chenhui Gao,Hong-Liang Dong,Qiao Zhong,Xiao-Ming Gao,Fang-Yuan Gong

DOI: https://doi.org/10.1038/s41598-017-04275-7

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Lactoferrin (LTF), an important first line defense molecule against infection, is a common target for humoral autoimmune reactions in humans. Since LTF is a multifunctional protein capable of activating innate immune cells via various surface receptors, we hypothesized that LTF-containing immune complexes (ICs) (LTF-ICs), likely formed in patients with high titer anti-LTF autoantibodies, could possess unique monocyte/macrophage-activating properties compared with other ICs. ELISA analysis on serum samples from rheumatoid arthritis (RA) patients (n = 80) and healthy controls (n = 35) for anti-LTF autoantibodies confirmed a positive correlation between circulating LTF-specific IgG and RA. ICs between human LTF and LTF-specific IgG purified from patient sera or immunized rabbits and mice, but not control ICs, LTF or Abs alone, elicited strong production of TNF-α and IL-1β by freshly fractionated human peripheral blood monocytes and monocytes-derived macrophages. Furthermore, LTF-ICs utilized both membrane-anchored CD14 and CD32a (FcγRIIa) to trigger monocyte activation in an internalization-, Toll-like receptor (TLR)4- and TLR9-dependent manner, and also that LTF-IC-induced cytokine production was blocked by specific inhibitors of caspase-1, NF-κB and MAPK. These results uncover a possible pathway for LTF-ICs perpetuating local inflammation and contributing to the pathogenesis of autoimmune diseases by triggering activation of infiltrating monocytes or tissue macrophages in vivo .
A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

WS Qin,JN Feng,W Zhang,Y Li,BF Shen

DOI: https://doi.org/10.1016/j.bbrc.2004.07.208

IF: 3.1

2004-01-01

Biochemical and Biophysical Research Communications

Abstract:The variable regions of antibody molecules bind antigens with high affinity and specificity. The binding sites are imparted largely to the hypervariable portions (i.e., CDRs) of the variable region. Peptides derived from CDRs can bind antigen with similar specificity acting as mimic of antibody and become drug-designing core, although with markedly lower affinity. In order to increase the affinity and bioactivity, in this study, a novel peptide (PT) designed on CDRs of a TNFalpha neutralizing monoclonal antibody Z12 was linked with Fc fragment of human IgG1. The interaction mode of PT-linker-Fc (PLF) with TNFalpha was analyzed with computer-guided molecular modeling method. After expression in Escherichia coli and purification, recombinant PT-linker-Fc could bind directly with the TNFalpha coated on the ELISA plates. Furthermore, PLF could competitively inhibit the binding of Z12 to TNFalpha and also inhibit the TNFalpha-induced cytotoxicity on L929 cells. The TNFalpha antagonizing activity of PLF was significantly higher than that of the free peptide. This study highlights the potential of human Fc to enhance the potency of peptides designed on the CDRs of antibodies and could be useful in developing new TNFalpha antagonists.

[Sclerema and scleredema of the newborn].

From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Inhibition of human lymphocyte reactivity by plasma fibronectin in vitro

Low molecular weight heparin inhibits circulating fibrocytes differentiation by modulating neuronal nitric oxide synthase and TGF-β1/Smad pathway.

Prospective Evaluation of Subjects With Chronic Asymptomatic Pancreatic Hyperenzymemia

Protective Effect of an Antibody Against Specific Extracellular Domain of TLR2 on Agonists-Driven Inflammatory and Allergic Response.

A Novel Anti-Tissue Factor Monoclonal Antibody with Anticoagulant Potency Derived from Synthesized Multiple Antigenic Peptide Through Blocking FX Combination with TF

Inflammatory Cytokine-Neutralizing Antibody Treatment Prevented Increases in Follicular Helper T Cells and Follicular Regulatory T Cells in a Mouse Model of Arthritis.

Locally instilled tumor necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs.

Formononetin Inhibits Mast Cell Degranulation to Ameliorate Compound 48/80-Induced Pseudoallergic Reactions

[Delayed growth with raised circulating growth hormone and incapacity to produce somatomedin (dwarfism of Laron type)].

TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism

Life-threatening right ventricular thrombosis in association with phospholipid antibodies.

Diagnosis and Management of Dry-Eye Syndrome

Anticoagulation Inhibition Effects of the Monoclonal Antibody Aginst the Recombinant Human Tissue Factor Pathway Inhibitor 1 on Rhtfpi

Locally instilled tumor necrosis factor α antisense oligonucleotide contributes to inhibition of TH2-driven pulmonary fibrosis via induced CD4+CD25+Foxp3+ regulatory T cells

Monovalent Fc Receptor Blockade by an Anti–fcγ Receptor/albumin Fusion Protein Ameliorates Murine ITP with Abrogated Toxicity

Expression of vascular cell adhesion molecule-1 by vascular endothelial cells in immune and nonimmune inflammatory reactions in the skin.

Extraordinarily Potent Proinflammatory Properties of Lactoferrin-Containing Immunocomplexes Against Human Monocytes and Macrophages

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody